Tag: FDA

Lynozyfic is a bispecific antibody directing T cells to kill multiple myeloma cancer cells; multiple myeloma is the second most common blood cancer 

Kanadensiska Kardium meddelade under dagen att man genomfört en kapitalrekrytering om 250 miljoner USD för att stödja global kommersialisering av Globe® Pulsed Field System – en banbrytande plattform för behandling av förmaksflimmer med hjälp av behandlingstekniken pulsed field ablation (PFA). Den nu kommunicerade investeringen innebär att Kardium sammantaget attraherat över 350 miljoner USD från externa investerare under de senaste dryga tolv månaderna, vilket tillhör det absoluta toppskiktet i den nordamerikanska medicinteknikindustrin.

Join our two-day seminar designed for pharmaceutical, biopharmaceutical, biologics, and medical device professionals to master FDA inspections. Gain hands-on strategies to efficiently prepare, conduct, and respond. Includes slides, certificates, Q&A, and inspection handouts. Optimize outcomes.

-  500 subjects enrolled across the United States, the United Kingdom, France, Czech Republic, Switzerland, China, Taiwan, and Australia

TABER, ALBERTA, July 01, 2025 (GLOBE NEWSWIRE) -- FLEXIBLE SOLUTIONS INTERNATIONAL, INC. (NYSE Amex: FSI), is the developer and manufacturer of biodegradable polymers for oil extraction, detergent ingredients and water treatment as well as crop nutrient availability chemistry. Flexible Solutions also manufactures biodegradable and environmentally safe water and energy conservation technologies. FSI is also increasing its presense in the food and nutrition supplement manufacturing markets. Today the Company announces it has received payment of US$2.5million for assisting in developing a new food grade product.

SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company applying its proprietary Cloudbreak^® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that the Compensation and Human Capital Committee of its Board of Directors (Compensation Committee) granted non-qualified stock option awards and restricted stock units (RSUs) for an aggregate of 12,100 shares of its common stock to two new employees, pursuant to the Cidara Therapeutics, Inc. 2020 Inducement Incentive Plan, as amended (the Inducement Plan), with a grant date of June 30, 2025. The stock option has an exercise price of $48.71 per share, which is equal to the closing price of Cidara’s common stock on the grant date. The shares subject to the option will vest over four years, with 25% of the shares vesting on the one-year anniversary of the vesting commencement date and the balance of the shares vesting in a series of 36 successive equal monthly installments thereafter. All RSUs vest in four equal annual installments, with 1/4 vesting on each of the first, second, third and fourth anniversaries of the Quarterly Vesting Date (as defined below) that occurs during the calendar quarter that includes the date of grant. “Quarterly Vesting Date” means March 10, June 10, September 10 or December 10. The awards are subject to the award holder’s continuous service through each vesting date and to the terms and conditions of the Inducement Plan and the standard forms of grant agreements thereunder.

Clinicians’ Choice Testosterone Booster: Medically Reviewed and Endorsed by Leading Experts, Now Available Nationwide Without Prescription